The Conversation (0)
NeoGenomics announced the opening of its first international laboratory facility in Switzerland.
NeoGenomics (NASDAQ:NEO) announced the opening of its first international laboratory facility in Switzerland.
As quoted in the press release:
This expansion brings NeoGenomics’ unique Pharma Services menu to the European market and will benefit clients by offering greater continuity of services for European-based clinical trials.
Douglas M VanOort, NeoGenomics Chairman and CEO, stated, “We are very pleased to open our first Laboratory facility outside of the United States as we advance our strategy to be a worldwide leader in Oncology testing and compete in the market for global clinical trials testing. Our Pharma clients have expressed significant interest in the advanced testing services we are offering from this facility such as flow cytometry, fluorescent in-situ hybridization (FISH) and immunohistochemistry (IHC). We greatly appreciate the assistance and incentives we have received from the Canton of Vaud and look forward to strong growth as we expand our business in the European market.”
Click here to read the full press release.